Subscribe to our Newsletters !!
The connection between genes and traits is one of
Our customers depend on the high performance and r
Few names in the medical history have had a profou
Alembic Pharmaceuticals Limited appoints Mr. Manis
Cipla Limited (BSE: 500087; NSE: CIPLA EQ; and her
It is important to understand that natural remedie
Dear Readers, Welcome to the latest issue of The Magazine
According to reports, the Drugs Controller General of India has approved a trial of mixing two COVID-19 vaccines — Covishield & Covaxin.
The mix-and-match study will be conducted by Christian Medical College, Vellore, India Today reported.
The nod is granted approximately 11 days after the Subject Expert Committee of the CDSCO (Central Drugs Standard Control Organisation), recommended that a mix-and match trial be allowed.
The SEC panel also recommended that Bharat Biotech be allowed to conduct a study on interchangeability between its Covaxin vaccine and the currently under-trial adenoviral intramuscular vaccine candidate BBV154. The report stated that DCGI has yet to make a decision on this matter.
Meanwhile, a recent study by ICMR involving 98 people, 18 of whom had inadvertently received Covishield as first dose and Covaxin as the second in Uttar Pradesh showed that combining these two COVID-19 vaccines elicited better immunogenicity than two doses of the same vaccine.
